Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.

"REOLYSIN(R) administered as a one-hour infusion on a monthly schedule is safe and well-tolerated even in multiple doses," said Principal Investigator Dr. Sanjay Goel of the Montefiore Medical Center and Albert Einstein College of Medicine, New York. "This preliminary data suggests there is anti-tumour activity of REOLYSIN(R) administered as a single agent, and warrants further studies either alone or in combination with cytotoxic chemotherapy, which are currently being planned."

A total of 18 patients were treated in the escalating dosage trial to a maximum daily dose of 3x10(10) TCID(50) in a one-hour infusion. Of the 18 patients treated, eight demonstrated stable disease as measured by RECIST (Response Evaluation Criteria in Solid Tumours) including a patient with progressive breast cancer who experienced a 28.5% shrinkage in tumour volume. The trial was originally designed to demonstrate the safety of a single, one-hour infusion of REOLYSIN(R). During the treatment of the 4th cohort of patients however, Oncolytics applied for and was granted approval to allow subsequent patients to receive repeat monthly treatments of REOLYSIN(R). Of the patients eligible for retreatment, three patients received a range of two to seven one-hour infusions of REOLYSIN(R).

Toxicities possibly related to REOLYSIN(R) treatment in this trial were generally mild (grade 1 or 2) and included chills, fever and fatigue.

The primary objective of the Company's U.S. Phase I trial is to determine the maximum tolerated dose,
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:12/15/2014)... TARRYTOWN, N.Y. and BRIDGEWATER, N.J. ... Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and ... heart disease organizations to launch Cholesterol Counts , ... know about cholesterol, their numbers, and the risks associated ... to visit www. CholesterolCounts .com to take ...
(Date:12/15/2014)... 2014 Investor-Edge has initiated coverage on ... Eli Lilly and Company (NYSE: LLY ), Nektar ... SNY ), and Novartis AG (NYSE: NVS ). ... http://investor-edge.com/register . On Friday, December 12, 2014, ... Jones Industrial Average lost 1.79%, to finish the day at ...
(Date:12/15/2014)... 2014  Stephen Squires, CEO and founder of leading ... (OTCQB:QTMM), will be speaking at the launch event ... December 16th, 2014. The RCQM launch continues Rice University,s ... top faculty and students and by inviting the world,s ... "We have a long association with Rice ...
Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... , INDIANAPOLIS, Dec. 14 ... Road interchange has become a bit more colorful when 10 multicolored art ... going home , will eventually include 34 total pieces and was designed ... Design, through the Basile Center for Art, Design and Public Life. ...
... Dec. 14 Watson Pharmaceuticals, Inc. (NYSE: WPI ... help maintain the bone health of prostate cancer patients who ... million men are receiving ADT, a palliative treatment for prostate ... can cause bone loss and increase a man,s risk for ...
Cached Medicine Technology:Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... -- Immediate breast reconstruction after mastectomy has a low ... in breast cancer treatment, according to a new study. ... one or both breasts. Researchers looked at 170 ... reconstruction after mastectomy, including 13 women who had reconstruction ...
... , FRIDAY, July 1 (HealthDay News) -- A new study ... certain type of learning remarkable staying power. Over two ... or pattern from a larger group of images. They found ... When they were tested again one to two years later, ...
... A team of researchers led by ... Lelivre, at CNRS UPR-3212, Strasbourg, France has identified ... the mouse. Of paramount importance, the data generated suggest ... final size of the brain. Individuals with microcephaly ...
... a form of pulmonary fibrosis often do not get referred ... is associated with a higher death rate. Better ... to referral. (NEW YORK, NY, July 1, 2011) ... from unknown causes―is the predominant condition leading to lung transplantation ...
... R.I. [Brown University] The Obama administration turned a ... the Office of National Drug Control Policy released a ... Joe Biden. With a cover article in the July ... Association (JADA), dentists focus that spotlight on themselves ...
... News) -- U.S. military personnel are at significantly increased ... study has found. The physical demands of ... prevalence of the painful joint disease, the researchers suggested ... Arthritis & Rheumatism . "Surprisingly, little is known ...
Cached Medicine News:Health News:When It Comes to Memory, Practice Seems to Make Perfect 2Health News:JCI online early table of contents: July 1, 2011 2Health News:JCI online early table of contents: July 1, 2011 3Health News:JCI online early table of contents: July 1, 2011 4Health News:JCI online early table of contents: July 1, 2011 5Health News:JCI online early table of contents: July 1, 2011 6Health News:JCI online early table of contents: July 1, 2011 7Health News:JCI online early table of contents: July 1, 2011 8Health News:Delayed access to tertiary care associated with higher death rate from type of pulmonary fibrosis 2Health News:Research examines dentists' role in painkiller abuse 2Health News:Research examines dentists' role in painkiller abuse 3Health News:Military Members Face Raised Risk of Osteoarthritis: Study 2
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
The BioCheck LH ELISA is intended for the quantitative determination of luteinizing hormone (LH) in human serum. This assay is useful in the diagnosis and treatment of gonadal dysfunction....
... (LH) is a glycoprotein secreted by the ... and TSH, the intact LH molecule is ... These glycoproteins all have homologous alpha-subunits, however ... LH and FSH production and secretion are ...
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
Medicine Products: